Added 1 day ago Drug news

NICE recommends Humira (adalimumab) to treat hidradenitis suppurativa- AbbVie

The National Institute for Health and Care Excellence (NICE) recommended the use of Humira (adalimumab) from AbbVie for the treatment of moderate to severe hidradenitis suppurativa

Added 8 days ago Industry news

Allergan has acquired Akarna Therapeutics including AKN 083 farnesoid X receptor agonist for NASH

Allergan announced that the Company has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small...

Added 8 days ago Industry news

Allergan acquires Tobira Therapeutics for $1.695 billion and with it cenicriviroc and evogliptin

Allergan plc and Tobira Therapeutics, Inc. announced that they have entered into a definitive agreement under which Allergan will acquire...

Lifestyle modification and liraglutide (MODEL)

This is a 52 week, single center, open-labeled, randomized controlled trial.

A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as contraindications to weight loss...

Added 1 day ago

Setmelanotide for the treatment of early-onset POMC deficiency obesity

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare bi-allelic loss-of function POMC or PCSK1 genetic mutations.

Added 1 day ago

Aspiration therapy in asian patients

This research project will provide insight into the efficacy and safety of aspiration therapy in the management of obesity and its comorbidities in the Asian population, and will determine if there is a role for this novel...

Added 1 day ago

Loss of DRO1/CCDC80 results in obesity and promotes adipocyte differentiation

To investigate the role of DRO1 in obesity and adipogenesis in vivo, we generated a constitutive Dro1 knockout mouse model and analyzed the effect of DRO1 loss on body growth under standard and high fat diet feeding conditions.

Added 1 day ago

The obesity paradox: an endocrine perspective.

Obesity is a growing epidemic both in Australia and worldwide. Being overweight or obese is known to be adversely associated with multiple cardiovascular risk factors such as type 2 diabetes mellitus, lipid disorders and hypertension.

Added 1 day ago

Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.

Over the past 30 years, there has been a dramatic rise in global obesity prevalence, resulting in significant economic and social consequences.

Added 1 day ago

2016 European Guidelines on cardiovascular disease prevention in clinical practice

The present guidelines represent an evidence-based consensus of the 6th European Joint Task Force  involving 10 professional societies.This document has...

Added 4 months ago

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and treatment of HF. The principal...

Added 4 months ago

EASL Clinical Practice Guidelines on the management of benign liver tumours

Benign liver tumours are a heterogeneous group of lesions with different cellular origins, as summarized by an international panel of...

Added 5 months ago